Diabetes
Conditions
Keywords
hscrp, hgba1c, diabetes mellitus
Brief summary
Current evidence supports a central role of inflammation in the pathogenesis of atherosclerosis and diabetes \[57-60\]. Diabetes Mellitus type 2 is an inflammatory atherothrombotic condition associated with high prevalence of thrombotic cardiovascular disease. In patient with DM type 2, this inflammation is reflected by elevated plasma levels of several biomarkers of inflammation such as C-reactive protein (CRP) \[51-55\]. HsCRP is considered as a strong predictive of cardiovascular risks and death \[53, 61-72\]. Besides its predictive role in determining cardiovascular risk, there is some evidence that CRP may represent an active participant in atherogenesis \[54\]. CRP is expressed in human atherosclerotic plaques and both vascular cells and monocytes/macrophages appear to represent a significant source of CRP in the inflammatory vessel wall \[54\]. Among the DM risk factors (like hypertension, atherogenic dyslipidemia, insulin resistance, impaired fibrinolysis, inflammatory profile), definitely, inflammation is the neglected one. Moringa oleifera has been suggested to exert anti-inflammatory effects \[42\]\[43\]\[45\] and hypoglycemic property \[80\]. As with many reports of the nutritional or medicinal value of a natural product, there are an alarming number of purveyors of healthful food who are now promoting M. oleifera as a panacea. While much of this recent enthusiasm indeed appears to be justified, it is critical to separate scientific evidence from anecdote. Herein, the investigators will investigate the effects of Moringa oleifera leaves supplementation on levels of inflammatory marker specifically hsCRP, hgbA1c level and clinical outocome in diabetic patients through a cohort study.
Detailed description
We performed a prospective cohort study of adult diabetics who were given 12-weeks supplementation of Moringa oleifera. Plasma hsCRP and serum HgbA1c were compared before and after treatment with M. oleifera.
Interventions
DIETARY_SUPPLEMENTMoringa oleifera
12 weeks supplementation
Sponsors
Ospital ng Maynila Medical Center
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 75 Years
Healthy volunteers
Yes
Inclusion criteria
1. Male or female participants aged between 19 and 65 years of age. 2. They were diagnosed by the Internal Medicine resident or other physician as having Diabetes Mellitus using the following criteria stated by American Diabetes Association (ADA) 3. Participants should be willing to have their blood extracted for hsCRP and Hgba1c measurement before and after 12 weeks supplementation of M. oleifera. 4. Participants have available treatment partner. 5. Subjects who have been diagnosed with other diseases such as asthma, stroke, or hypertension was included in the trial provided since they are already medically stable and that these diseases are not listed as part of the
Exclusion criteria
.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Post treatment mean HsCRP | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Post treatment mean hgba1c | 12 weeks |
Outcome results
None listed